Parties have settled a lawsuit over claims that the antipsychotic drug Risperdal caused a young man to grow excessive breast tissue that had been set to start trial Monday.
The case N.F. v. Janssen Pharmaceuticals settled for a confidential sum last week. The case would have been the sixth to hit trial out of the Risperdal mass tort program, and the first to go before a jury since Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, was hit with a $70 million verdict over similar claims in July.
